Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

MND isn’t incurable, it’s underfunded ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...

Rebuilding the clinical trials landscape in the UK ...